Regulators approved two new oral treatments for uncomplicated gonorrhea, adding zoliflodacin (Nuzolvence) and gepotidacin (Blujepa) to the antibiotic armamentarium. Both agents received priority review and qualified infectious disease product designations, reflecting urgent need for effective alternatives as Neisseria gonorrhoeae develops resistance to current therapies. The approvals give clinicians additional oral options that may simplify outpatient management and relieve pressure on injectable regimens. Innoviva and GSK reported labeling and age indications; GSK’s Blujepa was also cleared for expanded use in younger patients. Public‑health experts noted the approvals are timely but emphasized continued surveillance for resistance and the need to preserve new antibiotics through stewardship programs.